#SyndaxPharma shares lost 17% of their value pre-market after the company said it abandoned development of a drug candidate for #idiopathicpulmonaryfibrosis (IPF).
@pharmaphorum.bsky.social@pharmaphorum.bsky.social
@pharmaphorum.bsky.social#SyndaxPharma shares lost 17% of their value pre-market after the company said it abandoned development of a drug candidate for #idiopathicpulmonaryfibrosis (IPF).